FDA approved Cotellic tablets (cobimetinib) for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib. Cobimetinib is not indicated for treatment of patients with wild-type BRAF melanoma.
MICHAEL ZINNER was named CEO and executive medical director of Miami Cancer Institute at Baptist Health South Florida.
THE AMERICAN COLLEGE OF RADIOLOGY and several colorectal cancer care advocacy groups urged Congress to pass the CT Colonography Screening for Colorectal Cancer Act, which would provide Medicare coverage for seniors who choose those screening exams.
ST. JUDE CHILDREN'S RESEARCH HOSPITAL, The Scripps Research Institute and other institutions launched the Human Dark Proteome Initiative, to focus on the portion of the proteome that does not adopt defined 3D structures.
SIDNEY KIMMEL CANCER CENTER at Johns Hopkins University made several personnel changes.
CITY OF HOPE announced several appointments to its faculty.
STUART ORKIN received Boston Children's Hospital's Lifetime Impact Award at the hospital's third annual Global Pediatric Innovation Summit.
A group of 42 organizations sent an open letter to a congressional committee urging them to consider the important role of the FDA in the regulation of laboratory-developed tests.
Rep. Mike Fitzpatrick accused top leaders of Brigham & Women's Hospital of retaliating against patient advocates Amy Reed and Hooman Noorchashm when a hospital administrator declared the couple a security threat and subjected them to a physical search.
What does it say about our national commitment to research integrity that the Department of Health and Human Services' Office of Research Integrity has concluded that a five-year ban on federal research funding for one individual researcher is a sufficient response to a case involving millions of taxpayer dollars, completely fabricated data, and hundreds to thousands of patients in invasive clinical trials?
